TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24224560

Group type: EXPERIMENTAL
Intervention: Recombinant viruslike particle influenza A (H7N9) vaccine
Number of subjects: 0
Study: 24224624

Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SC-EPOCH-RR
Number of subjects: 30
Study: 24224707

Group type: EXPERIMENTAL
Intervention: Low DKK-1 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased secreted frizzled related protein-3 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysregulated Wnt signaling
Number of subjects: 0
Study: 24224903

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (eight 2-min intervals of 8% oxygen) for 10 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham exposure to room air
Number of subjects: 8
Study: 24225051

Group type: EXPERIMENTAL
Intervention: 4-day course of corticosteroid treatment
Number of subjects: 73

Group type: COMPARATOR
Intervention: No corticosteroid treatment
Number of subjects: 73
Study: 24225220

Group type: EXPERIMENTAL
Intervention: Heated humidified high flow nasal cannulae (HHHFNC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 20
Study: 24225354

Group type: EXPERIMENTAL
Intervention: Unconditional and conditional maternal weight standards developed and validated.
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Conditional standards
Number of subjects: 358
Study: 24225610

Group type: EXPERIMENTAL
Intervention: Best practice alert (BPA) tool with stewardship recommendations and access to the navigator
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Best practice alert (BPA) tool
Number of subjects: 1285
Study: 24225725

Group type: EXPERIMENTAL
Intervention: INVOS sensor (a trend monitor using two infrared wavelengths)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FORE-SIGHT sensor (a monitor using four wavelengths of laser light)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Comparison of INVOS and FORE-SIGHT
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both monitors
Number of subjects: 29
Study: 24226257

Group type: EXPERIMENTAL
Intervention: Geneva Risk Score
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Padua Prediction Score
Number of subjects: 1478
Study: 24227820

Group type: EXPERIMENTAL
Intervention: Crenolanib
Number of subjects: 0
Study: 24228627

Group type: EXPERIMENTAL
Intervention: Short cervix (<25 mm)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Presence of IL-8 in vaginal secretions
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combination of short cervix and IL-8
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Short inflamed cervix (short cervix with IL-8)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Overall sPTB occurrence
Number of subjects: 87
Study: 24229439

Group type: EXPERIMENTAL
Intervention: Subcutaneous-allergen-specific-immunotherapy (SCIT)
Number of subjects: 248
Study: 24232700

Group type: EXPERIMENTAL
Intervention: Intrabronchial valve treatment
Number of subjects: 10
Study: 24232703

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24234516

Group type: EXPERIMENTAL
Intervention: p53 antibody testing in patients with thyroid cancer
Number of subjects: 171

Group type: COMPARATOR
Intervention: p53 antibody testing in healthy subjects
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: p53 antibody testing in dedifferentiated patients with high Tg level and negative radioiodine scan
Number of subjects: 171
Study: 24237764

Group type: EXPERIMENTAL
Intervention: Higher resting heart rate (HR)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Lower resting heart rate (HR)
Number of subjects: 522
Study: 24237790

Group type: EXPERIMENTAL
Intervention: Nivestim™ (filgrastim) as primary or secondary prophylaxis for febrile neutropenia (FN) or as treatment for ongoing FN.
Number of subjects: 2530

Group type: EXPERIMENTAL
Intervention: Nivestim™ therapy
Number of subjects: 2530

Group type: EXPERIMENTAL
Intervention: Nivestim™
Number of subjects: 2530
Study: 24239220

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin combined with ABVD
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin combined with AVD
Number of subjects: 51
Study: 24240617

Group type: EXPERIMENTAL
Intervention: Website providing disease-specific safety information
Number of subjects: 108
Study: 24240933

Group type: EXPERIMENTAL
Intervention: Novel LDL-C estimation method (LDL-CN) using an adjustable factor for the TG:VLDL-C ratio
Number of subjects: 1350908

Group type: COMPARATOR
Intervention: Friedewald LDL-C (LDL-CF)
Number of subjects: 1350908

Group type: EXPERIMENTAL
Intervention: Novel LDL-C estimation method (LDL-CN)
Number of subjects: 1350908
Study: 24240934

Group type: EXPERIMENTAL
Intervention: TAVR (Edwards Sapien XT device)
Number of subjects: 7710
Study: 24241210

Group type: EXPERIMENTAL
Intervention: Flavopiridol (30 mg/m² bolus, 30 mg/m² continuous infusion to 50 mg/m² bolus, and 50 mg/m² continuous infusion)
Number of subjects: 15
Study: 24241533

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20
Study: 24242823

Group type: EXPERIMENTAL
Intervention: Nonhypertensive African American offspring
Number of subjects: 1035
Study: 24242861

Group type: EXPERIMENTAL
Intervention: AS1411 (40 mg/kg/day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: AS1411
Number of subjects: 35
Study: 24243422

Group type: EXPERIMENTAL
Intervention: Voclosporin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Covariate analysis for CL/F
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Covariate analysis for S0
Number of subjects: 87
Study: 24243635

Group type: EXPERIMENTAL
Intervention: Maternal fasting glucose
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Maternal 2-hour glucose
Number of subjects: 1247
Study: 24243787

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE) from the pulmonary artery
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE) from the coronary sinus
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 76
Study: 24244090

Group type: EXPERIMENTAL
Intervention: FES-assisted walking intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Aerobic/resistance training (control)
Number of subjects: 34
Study: 24245549

Group type: EXPERIMENTAL
Intervention: Celecoxib & Ursodeoxycholic acid (UDCA), n = 14
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Celecoxib & Placebo, n = 13
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal appearing mucosa of patients with FAP
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-FAP patient controls, n = 16
Number of subjects: 37
Study: 24246044

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 4427

Group type: EXPERIMENTAL
Intervention: OAB-5D
Number of subjects: 4427
Study: 24246506

Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel (15 mg/m² IV) with timed thoracic radiotherapy (TTR) (total 55 Gy) followed by adjuvant chemotherapy (carboplatin AUC 5 on day 1, gemcitabine 1000 mg/m² on days 1 and 8, every 21 days for 4 cycles)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel with concurrent TTR
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine/carboplatin
Number of subjects: 27
Study: 24246622

Group type: EXPERIMENTAL
Intervention: Nuss procedure
Number of subjects: 327
Study: 24246704

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg orally per day, with dose escalation by 25mg every two weeks until grade 2/tolerable rash or other dose limiting toxicity developed.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Erlotinib dose escalation to the development of grade 2 skin rash.
Number of subjects: 137

Group type: COMPARATOR
Intervention: Comparison to first-line chemotherapy.
Number of subjects: 137
Study: 24246789

Group type: EXPERIMENTAL
Intervention: Caregiver Pain Medicine Questionnaire
Number of subjects: 0
Study: 24247327

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (<75 nmol/L)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Each unit higher 25-hydroxyvitamin D levels at baseline
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 677
Study: 24247415

Group type: EXPERIMENTAL
Intervention: Intracoronary stem cell delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24248178

Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels measured in winter
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels measured in spring and summer
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels measured in fall
Number of subjects: 314
Study: 24248942

Group type: EXPERIMENTAL
Intervention: Very large HDL subclasses
Number of subjects: 26332

Group type: EXPERIMENTAL
Intervention: Large HDL subclasses
Number of subjects: 26332

Group type: EXPERIMENTAL
Intervention: Medium HDL subclasses
Number of subjects: 26332

Group type: EXPERIMENTAL
Intervention: Small HDL subclasses
Number of subjects: 26332

Group type: EXPERIMENTAL
Intervention: Very small HDL subclasses
Number of subjects: 26332
Study: 24249049

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment
Number of subjects: 935
Study: 24249802

Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) assessments using Teller acuity cards as the primary endpoint.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) assessments using HOTV as a secondary endpoint.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of optic disc for pallor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of visual quality of life using the Children's Visual Function Questionnaire.
Number of subjects: 0
Study: 24249967

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RESMENA group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both dietary strategies
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Higher SERPINE1 methylation levels at baseline
Number of subjects: 46
Study: 24251951

Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (HOMA-IR >4)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin-sensitive group (HOMA-IR ≤ 4)
Number of subjects: 22
Study: 24252049

Group type: EXPERIMENTAL
Intervention: Adalimumab with concomitant use of methotrexate (MTX)
Number of subjects: 7740

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 7740

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 7740
Study: 24252402

Group type: EXPERIMENTAL
Intervention: MK-2206 (60 mg QOD schedule)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MK-2206 (135 mg QW schedule)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of MK-2206 and trastuzumab
Number of subjects: 34

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 34
Study: 24253138

Group type: EXPERIMENTAL
Intervention: Extended heparin prophylaxis (4 weeks)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Short heparin prophylaxis (1 week)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 225
Study: 24254708

Group type: EXPERIMENTAL
Intervention: Drug-eluting absorbable metal scaffold
Number of subjects: 46
Study: 24254965

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 40
Study: 24255769

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: VATS surgical approach
Number of subjects: 133

Group type: COMPARATOR
Intervention: Open thoracotomy surgical approach
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen
Number of subjects: 133
Study: 24256329

Group type: EXPERIMENTAL
Intervention: Low-dose rate brachytherapy
Number of subjects: 604
Study: 24257381

Group type: EXPERIMENTAL
Intervention: AnaConDa® (ACD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 6
Study: 24257514

Group type: EXPERIMENTAL
Intervention: Raw vegetable intake (68 g per 1000 kcal)
Number of subjects: 2195

Group type: EXPERIMENTAL
Intervention: Cooked vegetable intake (92 g per 1000 kcal)
Number of subjects: 2195
Study: 24258465

Group type: EXPERIMENTAL
Intervention: E7107 at 5.7 mg/m(2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: E7107 at 4.3 mg/m(2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: E7107 (various doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: E7107 (3.2 mg/m(2) and 4.3 mg/m(2))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: E7107
Number of subjects: 26
Study: 24259241

Group type: COMPARATOR
Intervention: Cesarean delivery
Number of subjects: 129

Group type: COMPARATOR
Intervention: Respiratory support
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Study population
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 129
Study: 24259445

Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 3303

Group type: COMPARATOR
Intervention: Non-CTO PCI
Number of subjects: 3303
Study: 24260259

Group type: EXPERIMENTAL
Intervention: EV71 subgenotype C4 vaccines
Number of subjects: 119

Group type: COMPARATOR
Intervention: Sera from pediatric patients recovering from EV71-induced HFMD
Number of subjects: 119

Group type: COMPARATOR
Intervention: Sera from subclinically infected participants
Number of subjects: 119
Study: 24261337

Group type: EXPERIMENTAL
Intervention: Toolkit of strategies for non-clinician panel management assistants (PMAs) to enhance panel-wide outcomes in smoking cessation and hypertension.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toolkit strategies grouped into 5 areas: continuous connection to care, education and connection to clinical resources, targeted behavior change counseling, adherence support, and patients with special needs.
Number of subjects: 0
Study: 24261605

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (CEIs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no anti-dementia drugs)
Number of subjects: 120
Study: 24261996

Group type: EXPERIMENTAL
Intervention: BPZE1 administered intranasally before RSV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPZE1 administered neonatally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPZE1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-IL-17 antibodies
Number of subjects: 0
Study: 24262016

Group type: EXPERIMENTAL
Intervention: Procedures performed (chest tube removal, wound drain removal, arterial line insertion)
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Opioid administration specifically for the procedure
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Preprocedural pain intensity
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Preprocedural pain distress
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Intensity of the worst pain on the same day, before the procedure
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Procedure not performed by a nurse
Number of subjects: 3851

Group type: EXPERIMENTAL
Intervention: Overall procedural pain intensity
Number of subjects: 3851
Study: 24262504

Group type: EXPERIMENTAL
Intervention: Urine neutrophil gelatinase-associated lipocalin (uNGAL) measured within 24 hours of bypass, normalized to creatinine.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: uNGAL levels measured at various time points post-surgery.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clusterization algorithm applied to uNGAL kinetics.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Number needed to screen (NNS) to identify risk of dialysis or death.
Number of subjects: 200
Study: 24263064

Group type: EXPERIMENTAL
Intervention: gefitinib 250 mg day(-1) until progression
Number of subjects: 106
Study: 24263116

Group type: EXPERIMENTAL
Intervention: Optimal multisite left ventricular pacing (MSLV) configuration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: At least 1 MSLV configuration
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Optimal MSLV configuration
Number of subjects: 52
Study: 24263462

Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa (60 U/kg for treatment-naïve patients; 15-60 U/kg for previously treated patients)
Number of subjects: 211
Study: 24264034

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.45%, 4 times daily, for 3 days before surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.45%
Number of subjects: 24
Study: 24264395

Group type: EXPERIMENTAL
Intervention: Diabetes control interventions, specific details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study: 24265000

Group type: EXPERIMENTAL
Intervention: M-mode echocardiography
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 2D echocardiography
Number of subjects: 169

Group type: COMPARATOR
Intervention: M-mode or 2D echocardiography
Number of subjects: 169
Study: 24265370

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia for ten nights
Number of subjects: 0
Study: 24265415

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with weight loss (MedDiet-WL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mediterranean diet without weight loss (MedDiet+WL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: North American isoenergetic control diet
Number of subjects: 19
Study: 24265670

Group type: EXPERIMENTAL
Intervention: Rapamycin (preventive treatment for 25 days starting one day before myosin immunization)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapamycin (curative treatment for 10 days following the last myosin immunization)
Number of subjects: 0
Study: 24265828

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous rituximab
Number of subjects: 0
Study: 24267310

Group type: EXPERIMENTAL
Intervention: Novel medical therapies for pulmonary arterial hypertension
Number of subjects: 0
Study: 24267361

Group type: EXPERIMENTAL
Intervention: Area under the expiratory flow-volume curve (Aex) measurement during exercise treadmill challenge (ETC)
Number of subjects: 221
Study: 24267370

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24267809

Group type: EXPERIMENTAL
Intervention: Bupropion therapy
Number of subjects: 773
Study: 24268114

Group type: EXPERIMENTAL
Intervention: Computed FFR (FFRCT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Coronary CTA
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 270
Study: 24268213

Group type: EXPERIMENTAL
Intervention: Noninvasive imaging and assessment for cardiovascular risk factors, including lifestyle and psychosocial factors.
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: (18)F-fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging ((18)FDG PET/MRI) study of carotid and iliofemoral arteries in a subgroup of 1300 participants.
Number of subjects: 4000
Study: 24268517

Group type: EXPERIMENTAL
Intervention: Measurements obtained by independent observers reviewing preoperative CT scans.
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Measurements obtained by investigators (extent of aneurysm, target vessel stenosis, and aortic diameters).
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Measurements obtained from manufacturers (proximal landing zone, device diameter, and target vessel position).
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Critical discrepancies found in measurements.
Number of subjects: 268
Study: 24268783

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme intake after 2 hours during continuous feeding for 6 hours.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy subjects (control group).
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Measurement of whole-body citrulline production rate.
Number of subjects: 19
Study: 24269266

Group type: EXPERIMENTAL
Intervention: Chronic Mountain Sickness (CMS) patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy high-altitude (HA) dwellers
Number of subjects: 46
Study: 24269855

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 56
Study: 24270505

Group type: EXPERIMENTAL
Intervention: β blockers started during hospital admission for myocardial infarction
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Patients already taking β blockers before myocardial infarction
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: β blockers started during hospital admission for myocardial infarction (follow-up from discharge)
Number of subjects: 1063
Study: 24271095

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical diaphragmatic stimulation (TEDS)
Number of subjects: 15
Study: 24273046

Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine over 24 weeks
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: docetaxel followed by capecitabine over 36 weeks
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: trastuzumab-treated patients with HER2-positive disease
Number of subjects: 1495

Group type: COMPARATOR
Intervention: chemotherapy alone (HER2-negative disease)
Number of subjects: 1495
Study: 24273135

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin (40 mg/m² on day 1), vincristine (2 mg on day 1), dexamethasone (40 mg on days 1-4), lenalidomide (10 mg on days 1-21 of every 28-day cycle) followed by lenalidomide maintenance therapy.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy (at last tolerated dose until progression, with or without 50 mg prednisone every other day).
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with refractory disease.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Induction therapy (combination of drugs mentioned).
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (combination of drugs mentioned).
Number of subjects: 76